Targeting the mTOR signaling pathway in Autoimmune Lymphoproliferative Syndrome

靶向自身免疫性淋巴增殖综合征中的 mTOR 信号通路

• 批准号: 8317011
• 负责人: David T. Teachey
• 金额: $ 43.23万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-17 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8317011
• 关键词: Affect; Aftercare; Animals; Apoptosis; Atypical lymphocyte; Autoimmune Diseases; Autoimmune Process; Automobile Driving; Biology; Cells; Child; Childhood; Clinical; Cytokine Signaling; Data; Disease; Effector Cell; Goals; Homeostasis; Human; Immune; Immune system; Immunosuppression; Immunosuppressive Agents; In Vitro; Interleukin-10; Lead; Lymphatic Diseases; Lymphocyte; Lymphocyte Biology; Lymphocyte Subset; Lymphoid; Lymphoma; Malignant Neoplasms; Mediating; Modeling; Mus; Neoplasms; Pathologic; Pathology; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Population; Precancerous Conditions; Production; Protein-Serine-Threonine Kinases; Quality of life; Refractory; Regulatory T-Lymphocyte; Relative (related person); Resolution; Risk; Signal Pathway; Signal Transduction; Sirolimus; Sorting - Cell Movement; Splenomegaly; Supporting Cell; System; T-Cell Immunodeficiency; T-Lymphocyte; Testing; Transgenic Mice; Transgenic Organisms; Xenograft Model; apoptosis in lymphocytes; autoimmune lymphoproliferative syndrome; base; cytokine; cytopenia; effective therapy; human FRAP1 protein; improved; in vivo; inhibitor/antagonist; mTOR Inhibitor; mTOR Signaling Pathway; mTOR inhibition; mouse model; novel; prevent; response; treatment strategy